GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

21

SPINK1 p.Asn34Ser: Gastroenterology | May 2026

Introduction The SPINK1 gene encodes the pancreatic secretory trypsin inhibitor, a key protective molecule that prevents premature trypsin activation within the pancreas. Dysfunction of this pathway is central...

22

Gallbladder Polyps: Are We Still Over-Operating Despite New Guidelines? UEG Journal | July 2026

Introduction Gallbladder polyps are commonly detected incidentally, with a prevalence of up to 7% in adults. The vast majority are benign, while only a small fraction represent adenomas...

23

IPMN Surgery vs Surveillance: Annals of Surgical Oncology | April 2026

Introduction Intraductal papillary mucinous neoplasm presents a common yet challenging clinical dilemma—whether to operate or observe. The core issue is diagnostic uncertainty, as current imaging and clinical tools...

24

SMV Involvement in Pancreatic Cancer: Annals of Surgical Oncology | April 2026

Introduction Pancreatic ductal adenocarcinoma is a highly aggressive malignancy frequently involving adjacent vascular structures such as the superior mesenteric vein (SMV). Advances in surgical techniques now allow venous...

25

Fatty Pancreas in MASLD: JGH | March 2026

Introduction Metabolic dysfunction-associated steatotic liver disease is now recognized as a multisystem metabolic disorder affecting not only the liver but also cardiovascular, renal, and endocrine systems. Parallel to...

26

Tirzepatide and Acute Pancreatitis: Pancreatology | March 2026

Introduction With the rapid rise of obesity and type 2 diabetes, incretin-based therapies such as Tirzepatide have transformed metabolic care. These agents offer substantial benefits in weight reduction...

27

Peripancreatic Vascular Involvement in AIP: CGH | March 2026

Introduction Autoimmune pancreatitis (AIP) is a unique IgG4-related inflammatory disease with generally favourable outcomes following glucocorticoid therapy. However, beyond pancreatic inflammation, extension into the peripancreatic vasculature can occur,...

28

NAPAN Trial in Metastatic Pancreatic Cancer: EJC/ March 2026

Introduction: Metastatic pancreatic cancer continues to carry a dismal prognosis, with limited effective options after failure of first-line gemcitabine-based therapy. Liposomal irinotecan (nal-IRI) combined with 5-fluorouracil/leucovorin (5-FU/LV) is...

29

GOLP in High-Risk Resectable Intrahepatic Cholangiocarcinoma NEJM, March 2026

Introduction Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer and carries a poor prognosis even after curative surgery. Recurrence rates exceed 50%, particularly in patients...

30

Glucose Addiction in Cholangiocarcinoma: Hepatoma Research, 2025

Introduction Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is associated with poor prognosis due to late diagnosis and aggressive tumour biology. Increasing evidence links...

Previous
123456
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer